Key Drivers
- Liquidity softening
- Margin deterioration
- Weak cash generation
AIAI Summary
EVO is now a high-optionality, execution-dependent story: its partnership, AI, and J.TRAIN initiatives can only justify upside if they convert into durable gross margin and positive operating cash flow, because persistent losses, negative cash burn, and convertible-related dilution remain the main threats to the equity case.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Liquidity softening
- •Margin deterioration
- •Weak cash generation
EVO has adequate near-term liquidity and asset backing, but rising leverage, persistent losses, negative cash flow, and sharply worsening margins point to a weak and fragile financial profile.
Price Behavior
Key Price Behavior Insights:
- •Rebound Momentum
- •Support Reclaimed
- •Breakout Unconfirmed
EVO is stabilizing after a sharp mid-June selloff, with last month's rebound above $2.80–$2.85 showing improving short-term momentum, but a breakout still needs to clear resistance at $2.97.
Sharp drop from $2.97 to $2.56, then rebound to $2.90, signaling elevated short-term volatility
Sentiment & News
Key News Insights:
- •Governance continuity
- •Manufacturing expansion
- •Mixed clinical catalysts
Evotec is advancing governance and biologics manufacturing expansion with J.TRAIN, but partner-driven clinical results remain mixed after EVO756's setback, keeping pipeline sentiment uneven.
The news is modestly supportive operationally, but near-term upside may stay capped by continued dependence on partner clinical readouts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings